Your new post is loading...
OPN-305 from Opsona Therapeutics is a potent inhibitor of TLR mediated pro-inflammatory cytokine production
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Top Selling Monoclonal Antibodies |
Scoop.it!
Via Krishan Maggon
Research also suggests that the scope for TLR antagonists such as OPN-305 extends to other important inflammatory diseases including diabetes, lupus and Alzheimer's disease.
PatentsOpsona’s OPN-305 patent has recently been granted in a number of jurisdictions includingEurope (EP2451842B2) and the USA (US8,734,794B2). Opsona has several other patents surrounding OPN-305, including compositions, methods and epitope binding domains.